NCCN Guidelines® Insights: Acute lymphoblastic leukemia, version 1.2017: Featured updates to the NCCN Guidelines Journal Article
| Authors: | Brown, P. A.; Shah, B.; Fathi, A.; Wieduwilt, M.; Advani, A.; Aoun, P.; Barta, S. K.; Boyer, M. W.; Bryan, T.; Burke, P. W.; Cassaday, R.; Coccia, P. F.; Coutre, S. E.; Damon, L. E.; DeAngelo, D. J.; Frankfurt, O.; Greer, J. P.; Kantarjian, H. M.; Klisovic, R. B.; Kupfer, G.; Litzow, M.; Liu, A.; Mattison, R.; Park, J.; Rubnitz, J.; Saad, A.; Uy, G. L.; Wang, E. S.; Gregory, K. M.; Ogba, N. |
| Article Title: | NCCN Guidelines® Insights: Acute lymphoblastic leukemia, version 1.2017: Featured updates to the NCCN Guidelines |
| Abstract: | The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. However, the management of relapsed or refractory (R/R) ALL remains challenging and prognosis is poor. The NCCN Guidelines for ALL provide recommendations on standard treatment approaches based on current evidence. These NCCN Guidelines Insights summarize treatment recommendations for R/R ALL and highlight important updates, and provide a summary of the panel's discussion and underlying data supporting the most recent recommendations for R/R ALL management. © 2017 JNCCN-Journal of the National Comprehensive Cancer Network. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 15 |
| Issue: | 9 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2017-09-01 |
| Start Page: | 1091 |
| End Page: | 1102 |
| Language: | English |
| DOI: | 10.6004/jnccn.2017.0147 |
| PROVIDER: | scopus |
| PUBMED: | 28874594 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 October 2017 -- Source: Scopus |
